The effects of bone metabolism in different methylprednisolone pulse treatments for Graves' ophthalmopathy

Hu,Yong‑Xin; Zheng,Ren‑Dong; Fan,Yao‑Fu; Sun,Li; Hu,Xin; Liu,Chao

doi:10.3892/etm.2019.8179

The effects of bone metabolism in different methylprednisolone pulse treatments for Graves' ophthalmopathy

Authors:
- Yong‑Xin Hu
- Ren‑Dong Zheng
- Yao‑Fu Fan
- Li Sun
- Xin Hu
- Chao Liu
View Affiliations

Affiliations: Laboratory of Endocrinology and Metabolism, The Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210013, P.R. China, Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China
Published online on: November 8, 2019 https://doi.org/10.3892/etm.2019.8179
Pages: 333-338

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to analyze the effects of methylprednisolone pulse therapy (MPPT) courses on bone metabolism in patients with Graves' ophthalmopathy (GO). A retrospective analysis of 45 patients with moderate‑to‑severe active GO who received 1 or 2 courses of MPPT was performed. Of these, 16 patients underwent 2 courses of treatment. Bone metabolic markers and the density of the lumbar spine (L1‑4), femoral neck and total hip were measured using a dual‑energy X‑ray bone density instrument, and the differences in bone metabolism prior to and after treatment were determined for each group and compared. The results indicated that serum I collagen N‑terminal peptide (P1NP) and serum β‑collagen crosslinked C‑terminal peptide (CTX) were markedly decreased after the first pulse of treatment. In those patients who received a second course of MPPT, CTX levels were significantly decreased, but P1NP was not significantly different from the baseline value. CTX and P1NP levels remained unchanged between the first and second course of MPPT; similarly, there were no changes from baseline in 25(OH) vitamin D3 and bone mineral density after the first and second course of MPPT. However, the level of 25(OH) vitamin D3 was significantly elevated after the second course compared with the first course. In conclusion, the side effects of MPPT on bone metabolism were marginal and a second course of MPPT did not worsen bone metabolism. These MPPT regimens may therefore be considered to be a safe and effective treatment option for patients with moderate‑to‑severe active GO.

View Figures

View References

1	Wiersinga WM and Bartalena L: Epidemiology and prevention of Graves' ophthalmopathy. Thyroid. 12:855–860. 2002. View Article : Google Scholar : PubMed/NCBI
2	Wiersing WM: Advances in treatment of active, moderate- to-severe Graves' ophthalmopathy. Lancet Diabetes Endocrinol. 5:134–142. 2017. View Article : Google Scholar : PubMed/NCBI
3	Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I and Leibovici L: Treatment modalities for Graves' ophthalmopathy: Systematic review and meta-analysis. J Clin Endocrinol Metab. 94:2708–2716. 2009. View Article : Google Scholar : PubMed/NCBI
4	Gao G, Dai J, Qian Y and Ma F: Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy. Clin Exp Ophthalmol. 42:769–777. 2014. View Article : Google Scholar : PubMed/NCBI
5	Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, et al: Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 158:273–285. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zang S, Ponto KA and Kahaly GJ: Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: Efficacy and morbidity. J Clin Endocrinol Metab. 96:320–332. 2011. View Article : Google Scholar : PubMed/NCBI
7	Whittier X and Saag KG: Glucocorticoid-induced Osteoporosis. Rheum Dis Clin North Am. 42:177–168. 2016. View Article : Google Scholar : PubMed/NCBI
8	Bartley GB and Gorman CA: Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol. 119:792–795. 1995. View Article : Google Scholar : PubMed/NCBI
9	Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM; European Group on Graves, ; et al: The 2016 european Thyroid Association/European Group on Graves' Orbitopathy guidelines for the management of Graves' orbitopathy. Eur Thyroid J. 5:9–26. 2016. View Article : Google Scholar : PubMed/NCBI
10	Bahn R: High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: Where are we now? Thyroid. 22:1–2. 2012. View Article : Google Scholar : PubMed/NCBI
11	San Miguel I, Arenas M, Carmona R, Rutllan J, Medina-Rivero F and Lara P: Review of the treatment of Graves' ophthalmopathy: The role of the new radiation techniques. Saudi J Ophthalmol. 32:139–145. 2018. View Article : Google Scholar : PubMed/NCBI
12	Adler RA: Glucocorticoid-induced osteoporosis: Management challenges in older patients. J Clin Densitom. 22:20–24. 2019. View Article : Google Scholar : PubMed/NCBI
13	Compston J: Glucocorticoid-induced osteoporosis: An update. Endocrine. 61:7–16. 2018. View Article : Google Scholar : PubMed/NCBI
14	Yongxin H U, Li S, Shaofeng X, et al: Analysis of bone metabolism in patients with Graves' orbitopathy[J]. Jiangsu Medical Journal. 42:1875–1877. 2016.
15	Uedasakane Y, Kanamoto N, Fushimi Y, Tanaka-Mizuno S, Yasuno S, Miura M, Sone M, Yasoda A, Okada T, Togashi K, et al: Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy. Endocr J. 63:703–714. 2016. View Article : Google Scholar : PubMed/NCBI
16	Liu X, Wang S, Qin L, Qiang W, Dahal M, Fan P, Gao S and Shi B: Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy. Exp Ther Med. 12:901–908. 2016. View Article : Google Scholar : PubMed/NCBI
17	Miśkiewicz P, Kryczka A, Ambroziak U, Rutkowska B, Główczyńska R, Opolski G, Kahaly G and Bednarczuk T: Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe? Endokrynol Pol. 65:402–413. 2014. View Article : Google Scholar : PubMed/NCBI
18	Liu Y, Dimango E, Bucovsky M, Agarwal S, Nishiyama K, Guo XE, Shane E and Stein EM: Abnormal microarchitecture and stiffness in postmenopausal women using chronic inhaled glucocorticoids. Osteoporos Int. 29:2121–2127. 2018. View Article : Google Scholar : PubMed/NCBI
19	Leib ES and Winzenrieth R: Bone status in glucocorticoid-treated men and women. Osteoporos Int. 27:39–48. 2016. View Article : Google Scholar : PubMed/NCBI
20	Shen L, Ma C, Shuai B and Yang Y: Effects of 1,25-dihydroxyvitamin D3 on the local bone renin-angiotensin system in a murine model of glucocorticoid-induced osteoporosis. Exp Ther Med. 13:3297–3304. 2017. View Article : Google Scholar : PubMed/NCBI
21	Kenanidis E, Potoupnis ME, Kakoulidis P, Leonidou A, Sakellariou GT, Sayegh FE and Tsiridis E: Management of glucocorticoid-induced osteoporosis: Clinical data in relation to disease demographics, bone mineral density and fracture risk. Expert Opin Drug Saf. 14:1035–1053. 2015. View Article : Google Scholar : PubMed/NCBI
22	Shymanskyi I, Lisakovska O, Mazanova A, Labudzynskyi D and Veliky M: Vitamin D3 modulates impaired crosstalk between RANK and glucocorticoid receptor signaling in bone marrow cells after chronic prednisolone administration. Front Endocrinol (Lausanne). 9:3032018. View Article : Google Scholar : PubMed/NCBI
23	Sato AY, Richardson D, Cregor M, Davis HM, Au ED, McAndrews K, Zimmers TA, Organ JM, Peacock M, Plotkin LI and Bellido T: Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases. Endocrinology. 158:664–677. 2017.PubMed/NCBI